REDWOOD CITY, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the United States Patent and Trademark Office has granted OncoMed its first U.S. patent on its MAbTrap™ antibody display technology, one of the company's novel antibody platform technologies. OncoMed's MAbTrap™ technology enables the rapid identification of monoclonal antibodies that bind a particular target or set of targets, and bind such target or targets with high affinity and specificity. OncoMed has used the patented technology to identify and/or optimize novel antibodies, including proprietary bispecific antibodies, and demonstrated the activity of these antibodies in preclinical studies.
OncoMed Pharmaceuticals Receives First U.S. Patent On MAbTrap(TM) Antibody Display Technology
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.